Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,291,915 papers from all fields of science
Search
Sign In
Create Free Account
T 138067
Known as:
T-138067
, T138067
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
batabulin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin.
X. Ling
,
Xiang He
,
Pasha Apontes
,
Felicia Cao
,
R. Azrak
,
Fengzhi Li
American journal of translational research
2009
Corpus ID: 21540288
Growing evidence indicates that the antiapoptotic protein survivin is a major factor of drug and radiation resistance in cancer…
Expand
2007
2007
Enhancing efficacy of the multi-drug resistance-sensitive compound T138067 by advance treatment with negative modulators of the inhibitor of apoptosis protein survivin
Pasha Apontes
,
X. Ling
,
Y. Rustum
,
Fengzhi Li
2007
Corpus ID: 78393253
5164 Previous studies demonstrated that the aberrant expression of survivin, a protein with a central role in the inhibition of…
Expand
2004
2004
Synthesis, biodistribution and micro-PET imaging of radiolabeled antimitotic agent T138067 analogues.
X. Fei
,
Q. Zheng
,
+5 authors
G. Hutchins
Bioorganic & Medicinal Chemistry Letters
2004
Corpus ID: 28904136
2004
2004
Safety and pharmacokinetics (PK) of T138067 (T67) administered as a weekly 3-hour infusion in subjects with hepatocellular carcinoma (HCC) in a phase 1 study.
A. Venook
,
E. Rowinsky
,
R. Donehower
,
T. Leung
,
L. Floren
,
M. Levy
Journal of Clinical Oncology
2004
Corpus ID: 8375162
4087 Background: T67 is a novel irreversible tubulin inhibitor currently being studied in a pivotal trial for the treatment of…
Expand
2003
2003
Gateways to clinical trials.
M. Bayés
,
X. Rabasseda
,
J. Prous
Methods and Findings in Experimental and Clinical…
2003
Corpus ID: 27013008
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
2003
2003
Gateways to clinical trials.
M. Bayés
,
X. Rabasseda
,
J. Prous
Methods and Findings in Experimental and Clinical…
2003
Corpus ID: 32643595
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
2001
2001
Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier.
S. Rubenstein
,
V. Baichwal
,
+8 authors
J. Jaén
Journal of Medicinal Chemistry
2001
Corpus ID: 8127838
The novel anticancer compound T138067 is an irreversible inhibitor of tubulin polymerization. Amides 3-6 were synthesized using…
Expand
2000
2000
Tubulin as a target for anticancer drugs.
E. von Angerer
Current opinion in drug discovery & development
2000
Corpus ID: 23591981
Nature provides a large spectrum of agents that either inhibit the polymerization of tubulin or prevent the disassembly of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE